Elite in Prostate Cancer

Dr. Lauren C. Harshman

Oncology
450 Brookline Ave, Dana 1230, 
Boston, MA 
Elite in Prostate Cancer
450 Brookline Ave, Dana 1230, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lauren Harshman is an Oncologist in Boston, Massachusetts. Dr. Harshman is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 100 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 21 articles and participated in 7 clinical trials in the study of Prostate Cancer.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

450 Brookline Ave, Dana 1230, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Radium-223, Pembrolizumab
Study Phase: Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 29, 2024
Intervention Type: Drug
Study Drug: TAK-228
Study Phase: Phase 2
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drugs: Testosterone cypionate, Nivolumab
Study Phase: Phase 2
A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.
A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.
Enrollment Status: Completed
Publish Date: January 06, 2022
Intervention Type: Drug
Study Drugs: Crizotinib, Enzalutamide
Study Phase: Phase 1
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
Enrollment Status: Terminated
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Biological, Other
Study Phase: Phase 2
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Enrollment Status: Completed
Publish Date: June 09, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

100 Total Publications

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.
Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.
Journal: La Radiologia medica
Published: May 09, 2024
Similar Doctors
Elite in Prostate Cancer
Dr. Alicia K. Morgans
Oncology
Elite in Prostate Cancer
Dr. Alicia K. Morgans
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alicia Morgans is an Oncologist in Boston, Massachusetts. Dr. Morgans is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Urothelial Cancer, Prostatectomy, and Orchiectomy. Dr. Morgans is currently accepting new patients.

Elite in Prostate Cancer
Dr. Mark M. Pomerantz
Oncology | Hematology Oncology
Elite in Prostate Cancer
Dr. Mark M. Pomerantz
Oncology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Pomerantz is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Pomerantz is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Adrenal Cancer, Prostatectomy, and Orchiectomy. Dr. Pomerantz is currently accepting new patients.

Elite in Prostate Cancer
Dr. Atish D. Choudhury
Hematology Oncology | Hematology | Oncology
Elite in Prostate Cancer
Dr. Atish D. Choudhury
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Atish Choudhury is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Choudhury is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, WT1-Related Wilms Tumor Syndromes, and Prostatectomy. Dr. Choudhury is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harshman's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile